spacer
home > ict > winter 2017 > editor’s comment
PUBLICATIONS
International Clinical Trials

Editor’s Comment

In this edition, we highlight several aspects of patient recruitment and retention. Getting patients to participate in clinical trials is an ongoing challenge throughout the pharmaceutical industry. Stewart Rosen and Nicola J Smith at QuintilesIMS discusses how the human touch can alleviate some problems in subject recruitment. He notes that nearly two million patients take part in 80,000 companysponsored trials every year. However, as Ken Getz – founder of the Center for Information and Study on Clinical Research Participation – comments, companies are increasingly struggling to attract and retain the requisite number of participants to complete studies on time and within budget. It is estimated that almost half of all sites miss their enrolment targets. One solution proposed by Rosen and Smith is that nurses and other healthcare providers can play a crucial role as educators in the recruitment process; they feel that the function of these educators will expand as the number of clinical trials continues to rise.

Bruno Gagnon and Nick Payton at Comprehend discuss how patient centricity is a growing trend in the pharma sector and how this can result in patients being treated as consumers, rather than subjects.They describe how the three steps: leakage diagnosis, root causes of withdrawal and closing the loop, can help to retain patients by means of a proactive education of participants, which empowers them to make more informed decisions. The role of clinical operations is vital in this regard. Research nurses in particular – with respect to long-term medical conditions in clinical trials – are discussed by Julie Millar, Gaynor Mates and Louise Doyle at CK Aspire. They believe that studies carried out in ‘real world conditions’ can be complementary to traditional randomised clinical trials, and explore how research nurses must adapt to the varying examination methodologies when recruiting patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement